<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

A Knockout Jab for Breast Cancer?

Immunotherapy continues to be a hot topic in oncology research this year, with breast cancer vaccines showing promise in early phase clinical studies. Recently published research has shown that a vaccine targeting mammaglobin-A (which is expressed in the majority of breast cancers) is not only well-tolerated, but also shows surprisingly good efficacy in a Phase I study of metastatic disease.

Breast cancer is the most frequently diagnosed cancer type and second leading cause of cancer death in women around the world. In the US alone over 230,000 new cases of invasive breast cancer are expected to be diagnosed this year, with 40,000 women dying from the disease. On top of this, over 2,000 new cases in the US will also be diagnosed in men. While breast cancer is fairly well understood and can be split into many subgroups for initial treatment (mainly based on estrogen, progesterone, and HER2/neu biomarkers) metastasis remains a major problem. Metastatic breast cancer is currently incurable and has a poor US 5-year relative survival rate of only 22%.

Many research groups continue in the search for new treatments for both early stage and metastatic breast cancer, and a current hot topic is immunotherapeutics and particularly breast cancer vaccines. At the ASCO conference last year Phase I results were presented for a DNA vaccine that targets HER2, which is overexpressed in 15% to 20% of breast cancers. An exciting new Phase I study was then published in Clinical Cancer Research looking at a vaccine which targets mammaglobin-A (MAM-A) and which may be relevant in the treatment of up to 40% to 80% of breast cancer patients.

MAM-A is found pretty much exclusively in breast cancer. Overexpression of the protein in primary disease is thought to be as high as up to 80% in luminal breast cancer (which is usually estrogen receptor positive), and 40% to 50% in other breast cancer types, for example the particularly aggressive and difficult to treat triple negative breast cancer. This makes MAM-A a great target for a new cancer therapy as it could hopefully be used for the vast majority of patients with early stage and metastatic disease, where the protein is also found to be overexpressed. The vaccine works by priming white blood cells to target and destroy other cells presenting MAM-A, and the vaccination study was the first of this type against this target.

As this was a Phase I study, the main goal was to evaluate the safety of the vaccine in a small group of 14 subjects (including one male) with stable metastatic disease. The vaccine proved to be very well tolerated by patients, with no serious adverse events (Grade 3 or 4) reported during the trial. The most common mild side effect was flu-like symptoms, and the only moderate event was a case of shingles.

While safety objectives were the main goal of the study, CD8 T-cell response and progression-free survival (PFS) were also considered. An immune response was seen following vaccination, with an increase in both the frequency and number of MAM-A specific CD8 T-cells observed. Perhaps even more impressively PFS was shown to be significantly prolonged following vaccination (6-month PFS of 53% for treated subjects vs 33% for untreated screening failures). It is however important to note that this study was not specifically powered to look at this result. This is very promising Phase I data for a vaccine that could help the majority of breast cancer patients, and has the potential to be a prevention vaccine. These results come from a small study and further efficacy trials are now needed to look at the drug in a variety of breast cancer stages over a much larger group of patients.

Crown Bioscience is impressed to see such good early stage efficacy combined with an extremely well tolerated agent, and look forward to further results with this potential new therapy. We have a longstanding track record in breast cancer research with a range of platforms available for all stages of drug development, including hormone dependent, independent, and triple negative resources with both patient-derived xenograft and cell line derived xenograft models. Crown Bioscience also have a range of immunotherapy research platforms available for preclinical drug development, including platforms of mouse immunity and platforms of human immunity. Our immunology models of breast cancer include syngeneic and metastatic syngeneic models, GEMM models, and MuPrime™ models – which are allografts of spontaneous murine tumors, studied in mice with complete immunocompetency. Contact us at busdev@crownbio.com to talk to our experts about how Crown Bioscience can drive forward your breast cancer and immunotherapy research today.


Related Posts